Table 3.
Association between RGS17 expression and clinicopathological parameters in 87 cases of breast cancers.
| Total | RGS17 | P-value | r | ||||
|---|---|---|---|---|---|---|---|
| - | + | ++ | +++ | ||||
| n=3 | n=10 | n=18 | n=56 | ||||
| ER | |||||||
| Negative | 26 | 2 | 2 | 5 | 17 | 1.000 | -0.001 |
| Positive | 61 | 1 | 8 | 13 | 39 | ||
| PR | |||||||
| Negative | 41 | 2 | 3 | 8 | 28 | 0.478 | -0.077 |
| Positive | 46 | 1 | 7 | 10 | 28 | ||
| HER2 | |||||||
| Negative | 1 | 0 | 1 | 0 | 0 | 0.097 | 0.179 |
| Positive | 86 | 3 | 9 | 18 | 56 | ||
| p63 | |||||||
| Negative | 77 | 3 | 10 | 18 | 46 | 0.014* | 0.262 |
| Positive | 10 | 0 | 0 | 0 | 10 | ||
| Ki67 | |||||||
| ≤30% | 32 | 3 | 2 | 5 | 22 | 0.708 | -0.041 |
| >30% | 55 | 0 | 8 | 13 | 34 | ||
*p<0.05. ER, estrogen receptor; PR, progesterone receptor